

**(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE**

(11) Application No. AU 2007314076 B2

(54) Title
Organo-arsenoxide compounds and use thereof

(51) International Patent Classification(s)
C07F 9/74 (2006.01) **A61P 35/02** (2006.01)
A61K 31/285 (2006.01) **C07F 9/76** (2006.01)
A61P 35/00 (2006.01)

(21) Application No: **2007314076** (22) Date of Filing: **2007.11.01**

(87) WIPO No: **WO08/052279**

(30) Priority Data

(31) Number
2006906220 (32) Date
2006.11.01 (33) Country
AU

(43) Publication Date: **2008.05.08**
(44) Accepted Journal Date: **2012.07.19**

(71) Applicant(s)
NewSouth Innovations Pty Limited

(72) Inventor(s)
Dilda, Pierre;Hogg, Philip John

(74) Agent / Attorney
Spruson & Ferguson, Level 35 St Martins Tower 31 Market Street, Sydney, NSW, 2000

(56) Related Art
WO 2003/003011
WO 2003/039564
WO 2004/042079
WO 2001/021628
WO 2002/074305

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 May 2008 (08.05.2008)

PCT

(10) International Publication Number
WO 2008/052279 A1

(51) International Patent Classification:

C07F 9/74 (2006.01) A61P 35/00 (2006.01)
C07F 9/76 (2006.01) A61P 35/02 (2006.01)
A61K 31/285 (2006.01)

(74) Agent: SPRUSON & FERGUSON; GPO Box 3898, Sydney, NSW 2001 (AU).

(21) International Application Number:

PCT/AU2007/001676

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(22) International Filing Date:

1 November 2007 (01.11.2007)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2006906220 1 November 2006 (01.11.2006) AU

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).



(71) Applicant (for all designated States except US): NEW-SOUTH INNOVATIONS PTY LIMITED [AU/AU]; Rupert Myers Building, Gate 14, Barker Street, University of New South Wales, NSW 2052 (AU).

(72) Inventors; and

(75) Inventors/Applicants (for US only): HOGG, Philip, John [AU/AU]; 160 Prince Edward Street, Malabar, NSW 2036 (AU). DILDA, Pierre [FR/AU]; 5/108 Marine Parade, Maroubra, NSW 2035 (AU).

Published:

— with international search report

WO 2008/052279 A1

(54) Title: ORGANO-ARSENOXIDE COMPOUNDS AND USE THEREOF

(57) Abstract: The present invention relates to organo-arsenoxide compounds and to methods for their synthesis. The invention also relates to pharmaceutical compositions comprising these compounds and to their use in the treatment of diseases and disorders, in particular proliferative diseases and disorders, including treatment of solid tumors and leukaemia.

Organic-arsenoxide Compounds and Use Thereof

Technical Field

The present invention relates to organic-arsenoxide compounds and to methods for their synthesis. The invention also relates to pharmaceutical compositions comprising these 5 compounds and to their use in the treatment of diseases and disorders, including proliferative diseases and disorders.

Background of the Invention

Arsenical compounds have been used in the past as therapeutic agents for the treatment of disease. However, the inherent toxicities of arsenical compounds and their generally 10 unfavourable therapeutic index have essentially precluded their use as pharmaceutical agents.

Organic-arsenoxide compounds have been disclosed in WO 01/21628. Such compounds are described as having antiproliferative properties useful in the therapy of proliferative 15 diseases. WO 04/042079 discloses the use of organic-arsenoxide compounds for inducing the mitochondrial permeability transition (MPT) and the use of organic-arsenoxide compounds for inducing apoptosis, particularly in endothelial cells. The organic-arsenoxide compounds described in WO 01/21628 and WO 04/042079 have a substantially cell-membrane impermeable pendant group linked via a linking group to an 20 arsenoxide group. Neither WO 01/21628 nor WO 04/042079 specifically disclose compounds of formula (I) according to the present invention.

Patients with acute promyelocytic leukaemia (APL) can suffer relapse following treatment with the current therapy, all-trans retinoic acid. In such cases, arsenic trioxide is 25 considered the treatment of choice (Reiter et al., 2004). Arsenic trioxide is a trivalent arsenical that selectively kills APL cells. Arsenic trioxide is also showing promise for the treatment of myelodysplastic syndrome (Vey, 2004), a disease for which no standard treatment currently exists.

30 However, inorganic arsenicals, such as arsenic trioxide, have long been recognised as a poison and carcinogen when present in the body at levels that exceed its capacity to detoxify the metalloid and are associated with many adverse side effects.

There is a need for alternative therapies for treating proliferative diseases, such as cancer (including treatment of solid tumors), and related conditions. In particular, there is a need for alternative therapies for treating APL, including acute myelocytic leukaemia (AML). There is also a need for a therapeutic treatment for myelodysplastic syndrome.


5

The present invention relates to a group of arsenoxide compounds comprising an optionally substituted amino acid residue linked via a linking group to a phenylarsenoxide group. Compounds according to the present invention may have one or more advantage(s) over known arsenical compounds, such as arsenic trioxide and the arsenoxide compounds disclosed in WO 01/21628 or WO 04/042079, including the compound 4-(N-(S-glutathionylacetyl)amino)phenylarsenoxide (GSAO), particularly when used for the treatment of proliferative disease, such as cancer (e.g., solid tumors).

10

Summary of the Invention

In a first aspect the present invention relates to a compound of general formula (I):



wherein

the As(OH)₂ group may be ortho-, meta- or para- to the N-atom on the phenyl ring;

R¹ is selected from hydrogen and C₁₋₃ alkyl;

20 R² and R³ may be the same or different and are independently selected from hydrogen, optionally substituted C₁₋₃ alkyl, optionally substituted cyclopropyl, optionally substituted C₂₋₃ alkenyl; and optionally substituted C₁₋₃ alkoxy;

R⁴ and R⁵ may be the same or different and are independently selected from hydrogen, optionally substituted C₁₋₃ alkyl, optionally substituted cyclopropyl, optionally substituted C₂₋₃ alkenyl; and optionally substituted C₁₋₃ alkoxy;

m is an integer selected from 1, 2 and 3;

n is an integer selected from 1, 2 and 3;

* indicates a chiral carbon atom; and
salts and hydrates thereof.

5 In a second aspect the present invention relates to a pharmaceutical composition comprising at least one compound of formula (I) according to the first aspect of the invention, together with a pharmaceutically acceptable excipient, diluent or adjuvant.

10 In another aspect the present invention relates to a method of treating a proliferative disease in a vertebrate, the method comprising administering to the vertebrate a therapeutically effective amount of a compound of formula (I) according to the first aspect of the invention, or a composition according to the second aspect of the invention. The proliferative disease may be cancer, such as a solid tumour.

15 In a further aspect the present invention relates to a method of inhibiting angiogenesis in a vertebrate, comprising administering to the vertebrate an effective amount of a compound of formula (I) according to the first aspect of the invention, or a composition according to the second aspect of the invention.

20 In another aspect the present invention relates to a method of inducing the Mitochondrial Permeability Transition (MPT) in a vertebrate comprising administering to the vertebrate a therapeutically effective amount a compound of formula (I) according to the first aspect of the invention, or a composition according to the second aspect of the invention.

25 In a further aspect the present invention relates to a method of inducing apoptosis in proliferating mammalian cells, comprising administering to the mammal an apoptosis-inducing amount of a compound of formula (I) according to the first aspect of the invention, or a composition according to the second aspect of the invention.

30 In another aspect the invention relates to a method of treating leukaemia or myelodysplastic syndrome in a vertebrate, comprising administering to the vertebrate a therapeutically effective amount of a compound of formula (I) according to the first aspect of the invention, or a composition according to the second aspect of the invention.

35 In a further aspect the present invention relates to the use of at least one compound of formula (I) according to the first aspect of the invention in the manufacture of a

medicament for treating a proliferative disease in a vertebrate. The proliferative disease may be cancer, such as a solid tumour.

5 In another aspect the present invention relates to the use of at least one compound of formula (I) according to the first aspect of the invention in the manufacture of a medicament for inhibiting angiogenesis in a vertebrate.

10 In yet another aspect the present invention relates to the use of at least one compound of formula (I) according to the first aspect of the invention in the manufacture of a medicament for inducing the MPT in a vertebrate.

In a further aspect the present invention relates to the use of at least one compound of formula (I) according to the first aspect of the invention in the manufacture of a medicament for inducing apoptosis in proliferating mammalian cells.

15 In another aspect the present invention relates to the use of at least one compound of formula (I) according to the first aspect of the invention in the manufacture of a medicament for treating leukaemia in a vertebrate.

Definitions

20 The following are some definitions that may be helpful in understanding the description of the present invention. These are intended as general definitions and should in no way limit the scope of the present invention to those terms alone, but are put forth for a better understanding of the following description.

25 Unless the context requires otherwise or specifically stated to the contrary, integers, steps, or elements of the invention recited herein as singular integers, steps or elements clearly encompass both singular and plural forms of the recited integers, steps or elements.

30 Throughout this specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated step or element or integer or group of steps or elements or integers, but not the exclusion of any other step or element or integer or group of elements or integers. Thus, in the context of this specification, the term "comprising" means "including principally, but not necessarily solely".

Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also 5 includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations or any two or more of said steps or features.

In the context of this specification, BRAO refers to 4-(2-bromoacetylamino)-10 benzenearsonic acid; CAO refers to 4-(N-(S-cysteinylacetyl)amino)-phenylarsinous acid; GSAO refers to 4-(N-(S-glutathionylacetyl)amino)phenylarsinous acid; and PENAO refers to 4-(N-(S-penicillaminylacetyl)amino)phenylarsinous acid [“(S)-Penicillamine-arsenoxide”].

15 As used herein, the term "C₁₋₃ alkyl group" includes within its meaning monovalent ("alkyl") and divalent ("alkylene") straight chain or branched chain saturated aliphatic groups having from 1 to 3 carbon atoms. Thus, for example, the term C₁₋₃ alkyl includes methyl, ethyl, 1-propyl, and isopropyl.

20 The term "C₂₋₃ alkenyl group" includes within its meaning monovalent ("alkenyl") and divalent ("alkenylene") straight or branched chain unsaturated aliphatic hydrocarbon groups having from 2 to 3 carbon atoms and at least one double bond anywhere in the chain. Unless indicated otherwise, the stereochemistry about each double bond may be independently *cis* or *trans*, or *E* or *Z* as appropriate. Examples of alkenyl groups include 25 ethenyl, vinyl, allyl, 1-methylvinyl, 1-propenyl, and 2-propenyl.

The term "C₂₋₃ alkynyl group" as used herein includes within its meaning monovalent ("alkynyl") and divalent ("alkynylene") unsaturated aliphatic hydrocarbon groups having from 2 to 3 carbon atoms and having at least one triple bond. Examples of alkynyl groups 30 include but are not limited to ethynyl, 1-propynyl.

The term "alkoxy" as used herein refers to straight chain or branched alkyloxy (i.e., O-alkyl) groups, wherein alkyl is as defined above. Examples of alkoxy groups include methoxy, ethoxy, n-propoxy, and isopropoxy.

The term "amino" as used herein refers to groups of the form $-\text{NR}^a\text{R}^b$ wherein R^a and R^b are individually selected from hydrogen, optionally substituted (C_{1-4})alkyl, optionally substituted (C_{2-4})alkenyl, optionally substituted (C_{2-4})alkynyl, optionally substituted (C_{6-10})aryl and optionally substituted aralkyl groups, such as benzyl. The amino group 5 may be a primary, secondary or tertiary amino group.

In the context of this specification the term "arsenoxide" is synonymous with "arsinous acid" and refers to the moiety $\text{As}(\text{OH})_2$, which may also be represented as $\text{As}=\text{O}$.

10 The term "amino acid" as used herein includes naturally and non-naturally occurring amino acids, as well as substituted variants thereof. Thus, (L) and (D) forms of amino acids are included in the scope of the term "amino acid". The term "amino acid" includes within its scope glycine, alanine, valine, leucine, isoleucine, methionine, proline, phenylalanine, tryptophan, serine, threonine, cysteine, tyrosine, asparagine, glutamine, 15 aspartic acid, glutamic acid, lysine, arginine, and histidine. The backbone of the amino acid residue may be substituted with one or more groups independently selected from (C_{1-6})alkyl, halogen, hydroxy, hydroxy(C_{1-6})alkyl, aryl, e.g., phenyl, aryl(C_{1-3})alkyl, e.g., benzyl, and (C_{3-6})cycloalkyl.

20 The term " C_{6-10} aryl" or variants such as "arylene" as used herein refers to monovalent ("aryl") and divalent ("arylene") single, polynuclear, conjugated and fused residues of aromatic hydrocarbons having from 6 to 10 carbon atoms. Examples of aromatic groups include phenyl, and naphthyl.

25 The term "arylalkyl" or variants such as "aralkyl" as used herein, includes within its meaning monovalent ("aryl") and divalent ("arylene"), single, polynuclear, conjugated and fused aromatic hydrocarbon radicals attached to divalent, saturated, straight or branched chain alkylene radicals. Examples of arylalkyl groups include benzyl.

30 The term " C_{3-8} heterocycloalkyl" as used herein, includes within its meaning monovalent ("heterocycloalkyl") and divalent ("heterocycloalkylene"), saturated, monocyclic, bicyclic, polycyclic or fused hydrocarbon radicals having from 3 to 8 ring atoms, wherein from 1 to 5, or from 1 to 3, ring atoms are heteroatoms independently selected from O, N, NH, or S. The heterocycloalkyl group may be C_{3-6} heterocycloalkyl. The 35 heterocycloalkyl group may be C_{3-5} heterocycloalkyl. Examples of heterocycloalkyl

groups include aziridinyl, pyrrolidinyl, piperidinyl, piperazinyl, quinuclidinyl, azetidinyl, morpholinyl, tetrahydrothiophenyl, tetrahydrofuranyl, tetrahydropyranyl, and the like.

The term “C₅₋₂₀ heteroaromatic group” and variants such as “heteroaryl” or

5 “heteroarylene” as used herein, includes within its meaning monovalent (“heteroaryl”)

and divalent (“heteroarylene”), single, polynuclear, conjugated and fused aromatic radicals having from 5 to 20 atoms, wherein 1 to 6 atoms, or 1 to 4, or 1 to 2 ring atoms are heteroatoms independently selected from O, N, NH and S. The heteroaromatic group

may be C₅₋₁₀ heteroaromatic. The heteroaromatic group may be C₅₋₈ heteroaromatic.

10 Examples of heteroaromatic groups include pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, 2,2'-bipyridyl, phenanthrolinyl, quinolinyl, isoquinolinyl, imidazolinyl, thiazolinyl, pyrrolyl, furanyl, thiophenyl, oxazolyl, isoxazolyl, isothiazolyl, triazolyl, and the like.

The term “halogen” or variants such as “halide” or “halo” as used herein refers to

15 fluorine, chlorine, bromine and iodine.

The term “heteroatom” or variants such as “hetero-” as used herein refers to O, N, NH and S.

20 The term “optionally substituted” as used herein means the group to which this term refers may be unsubstituted, or may be substituted with one or more groups independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, halo, haloalkyl, haloalkynyl, hydroxyl, hydroxyalkyl, alkoxy, thioalkoxy, alkenyloxy, haloalkoxy, haloalkenyloxy, NO₂, NR^aR^b, nitroalkyl, nitroalkenyl, nitroalkynyl, 25 nitroheterocyclyl, alkylamino, dialkylamino, alkenylamine, alkynylamino, acyl, alkenoyl, alkynoyl, acylamino, diacylamino, acyloxy, alkylsulfonyloxy, heterocycloxy, heterocycloamino, halo-heterocycloalkyl, alkylsulfenyl, alkylcarbonyloxy, alkylthio, acylthio, phosphorus-containing groups such as phosphono and phosphinyl, aryl, heteroaryl, alkylaryl, aralkyl, alkylheteroaryl, cyano, cyanate, isocyanate, CO₂H, CO₂alkyl, C(O)NH₂, -C(O)NH(alkyl), and -C(O)N(alkyl)₂. Preferred substituents include C₁₋₃ alkyl, C₁₋₃ alkoxy, -CH₂-(C₁₋₃)alkoxy, C₆₋₁₀ aryl, e.g., phenyl, -CH₂-phenyl, halo, hydroxyl, hydroxy(C₁₋₃)alkyl, and halo-(C₁₋₃)alkyl, e.g., CF₃, CH₂CF₃. Particularly preferred substituents include C₁₋₃ alkyl, C₁₋₃ alkoxy, halo, hydroxyl, hydroxy(C₁₋₃)alkyl, e.g., CH₂OH, and halo-(C₁₋₃)alkyl, e.g., CF₃, CH₂CF₃.

In the context of this specification the term “administering” and variations of that term including “administer” and “administration”, includes contacting, applying, delivering or providing a compound or composition of the invention to an organism, or a surface by any appropriate means.

5

In the context of this specification, the term “vertebrate” includes humans and individuals of any species of social, economic or research importance including but not limited to members of the genus ovine, bovine, equine, porcine, feline, canine, primates (including human and non-human primates), rodents, murine, caprine, leporine, and avian. In a preferred embodiment the vertebrate is a human.

10

In the context of this specification, the term “treatment”, refers to any and all uses which remedy a disease state or symptoms, prevent the establishment of disease, or otherwise prevent, hinder, retard, or reverse the progression of disease or other undesirable symptoms in any way whatsoever.

15

In the context of this specification the term “effective amount” includes within its meaning a sufficient but non-toxic amount of a compound or composition of the invention to provide a desired effect. Thus, the term “therapeutically effective amount” includes within its meaning a sufficient but non-toxic amount of a compound or composition of the invention to provide the desired therapeutic effect. The exact amount required will vary from subject to subject depending on factors such as the species being treated, the sex, age and general condition of the subject, the severity of the condition being treated, the particular agent being administered, the mode of administration, and so forth. Thus, it is not possible to specify an exact “effective amount”. However, for any given case, an appropriate “effective amount” may be determined by one of ordinary skill in the art using only routine experimentation.

Brief Description of the Figures

30

Figure 1. Structure of (S)-Penicillamine-arsenoxide (“PENAO”).

Figure 2. ^1H -NMR spectrum of (S)-Penicillamine-arsenoxide.

Figure 3. 2D ^1H - ^{13}C multiple bond correlation data for (S)-Penicillamine-arsenoxide.

35

Long-range coupling was observed between the acyl hydrogens of 4-(2-

bromoacetylarnino)benzenearsonic acid (“BRAO”) (δ 3.55) and the penicillamine quaternary carbon (δ 46.75). The NMR spectrum was recorded in D_2O on a 300MHz Bruker, dual channel probe NMR spectrometer.

5 **Figure 4.** Mass Spectrometry: sodiated mass peak observed at 413.011678 (δ 1.5ppm from calculated). Rapid alkyl ester formation occurs depending on the alcohol solvent used e.g, if the sample is run in methanol, the main peaks observed are +15 or +30 mass units.

10 **Figure 5.** (S)-Penicillamine-arsenoxide inhibits proliferation of BAE cells with an IC_{50} of 0.4 μ M. The pentavalent arsenical compound (S)-Penicillamine-arsenonic acid, has no effect on proliferation. The data points are mean \pm SD of three experiments performed in triplicate.

15 **Figure 6.** Comparison of the effects of (S)-Penicillamine-arsenoxide on BAE proliferation versus viability. The data points are mean \pm SD of three experiments performed in triplicate.

20 **Figure 7.** (S)-Penicillamine-arsenoxide is as good an inhibitor of APL cell proliferation as arsenic trioxide. Number of viable NB4 cells remaining after 72 h incubation with increasing concentrations of arsenic trioxide, Penicillamine-arsenoxide or GSAO. Data points are the mean \pm SD of triplicate determinations.

25 **Figure 8.** (S)-Penicillamine-arsenoxide is more efficient than GSAO at inducing the mitochondrial permeability transition. Mitochondrial swelling induced by 100 μ M GSAO or (S)-Penicillamine-arsenoxide as measured by decrease in light scattering at 520 nm over 30 min. The traces are representative of two experiments performed in duplicate on two different mitochondrial preparations.

30 **Figure 9.** (S)-Penicillamine-arsenoxide accumulates in BAE cells at a ~70-fold faster rate than GSAO. BAE cells were incubated for up to 4 h in presence of 50 μ M GSAO or (S)-Penicillamine-arsenoxide and cytosolic arsenic was measured by inductively coupled plasma spectrometry. The data points and error bars are the mean \pm SD of triplicate determinations and is representative of two experiments.

Figure 10. Inhibition of cell-surface OATP blunts cellular accumulation of (S)-Penicillamine-arsenoxide and anti-proliferative activity. **A.** Inhibition of (S)-Penicillamine-arsenoxide accumulation in endothelial cells by the OATP inhibitor, DIDS. Cells were pretreated or not with 500 μ M DIDS for 30 min and then incubated with 20 μ M (S)-Penicillamine-arsenoxide for 2 h. Arsenic content was determined by ICPMS. Values are mean \pm SD of triplicate determinations. The results are representative of two experiments. **: $p<0.01$. **B.** DIDS blunts GSAO anti-proliferative activity in endothelial cells. BAE cells were pretreated or not with 300 μ M DIDS for 30 min and then incubated with 1.5 μ M (S)-Penicillamine-arsenoxide for 24 h. Cell viability was determined using MTT. Results are expressed as percentage of control. Values are mean \pm SD of triplicate determinations. Results are representative of two experiments. **: $p<0.01$.

Figure 11. (S)-Penicillamine-arsenoxide is pumped out of cells by MRP1/2. **A** BAE cells were incubated for up to 2 h with 50 μ M (S)-Penicillamine-arsenoxide in the absence or presence of 4H10 (5 μ M) or MK-571 (25 μ M) and cytosolic arsenic was measured by inductively coupled plasma spectrometry. The data points and error bars are the mean \pm SD of quadruplicate determinations and is representative of two experiments. **B** Effect of the MRP1/2 inhibitors, 4H10 (2 μ M) and MK-571 (15 μ M), on Penicillamine-arsenoxide (0.3 μ M) inhibition of BAE cell proliferation. The MRP inhibitors were incubated for 30 min with the cells prior to incubation with (S)-Penicillamine-arsenoxide for 72 h. The data points and error bars are the mean \pm SD of triplicate determinations. *** is $p < 0.001$, ** is $p < 0.01$

Figure 12. Depletion of cellular glutathione increases (S)-Penicillamine-arsenoxide anti-proliferative activity. BAE cells were co-treated with (S)-Penicillamine-arsenoxide and the indicated concentrations of BSO for 72 h and the IC₅₀ for proliferation arrest was calculated. The data points and error bars are the mean \pm SD from two experiments performed in triplicate.

Figure 13. Inhibition of human pancreatic carcinoma tumour growth by continuous subcutaneous administration of (S)-Penicillamine-arsenoxide. BxPC-3 tumours were established in the proximal midline of female 7 to 9 week old BalbC nude mice. Mice bearing \sim 50 mm³ tumours were implanted with 28 day alzet micro-osmotic pumps subcutaneously in the flank. The pumps delivered 0.25, 0.5 or 1 mg/kg/day (S)-Penicillamine-arsenoxide in 100 mM glycine (vehicle).

Figure 14. Production of CAO by enzymatic cleavage of GSAO.**Figure 15.** HPLC analysis of GSAO and CAO. 5 nmoles of GSAO (part A) or CAO

5 (part B) was resolved on a C18 reverse phase column and detected by absorbance at 256 nm.

Figure 16. CAO accumulates more rapidly in cells and have greater anti-proliferative activity than GSAO. A. CAO accumulates in cells at a much faster rate than GSAO.

10 BAE cells were incubated with 50 μ M GSAO or CAO for 4 h. Cellular arsenic levels were determined by ICPMS. The rates of accumulation are GSAO and CAO are 0.03 and 0.20 nmol As atoms per 10^6 cells, respectively. Data points are the mean \pm SD of three determinations. The results are representative of two experiments. B. CAO is exported from cells by the multidrug resistance associated protein 1. BAE cells pretreated for 30

15 min with 10 μ M of the MRP-1 inhibitor 4H10 were incubated with 50 μ M GSAO or CAO for 2 h. Cellular arsenic levels were determined by ICPMS. Data points are the mean \pm SD of three determinations. The results are representative of two experiments. C. GSAO and CAO IC₅₀ values for proliferation arrest of endothelial cells. BAE cells were incubated with 0.8-100 μ M GSAO or CAO for 24, 48 or 72h. Cell viability was 20 determined using MTT. Results are expressed as percentage of control. Values are mean \pm SD of triplicate determinations. Results are representative of three experiments.

Figure 17. CAO triggers the mitochondrial permeability transition. Mitochondria were

25 incubated with nil (●), 150 μ M Ca²⁺ and 6 mM Pi (○) or 200 μ M CAO (▲) and swelling

monitored by decrease in light scattering at 520 nm over 60 min. The traces are representative of two experiments.

Detailed Description of Preferred Embodiments of the Invention

The present invention relates to organo-arsenoxide compounds comprising an optionally

30 substituted amino acid moiety linked via a linker group to a phenylarsenoxide group.

Organo-arsenoxide compounds in accordance with the present invention have a substituted or unsubstituted amino acid moiety. Examples of amino acid moieties include


cysteinyl, substituted cysteinyl, for example penicillaminy (also known as β,β -

35 dimethylcysteinyl or 3-mercaptopivalinyl), optionally substituted alaninyl, optionally

substituted mercaptoalananyl, optionally substituted valanyl, optionally substituted 4-mercaptopovalinyl, optionally substituted leucinyl, optionally substituted 3- or 4-, or 5-mercaptopoleucinyl, optionally substituted isoleucinyl, or optionally substituted 3-, 4- or 5-isoleucinyl. In a preferred embodiment of the invention the amino acid moiety is β,β -dimethylcysteinyl (“penicillaminyl”). In another embodiment of the invention the amino acid moiety is (S)-penicillaminyl. In another embodiment of the invention the amino acid moiety is cysteinyl. The amino acid moiety may have (L), (D), (R) or (S) configuration. Optional substituents include C_{1-3} alkyl, cyclopropyl, C_{1-3} alkoxy, $-CH_2-(C_{1-3})$ alkoxy, C_{6-10} aryl, $-CH_2$ -phenyl, halo, hydroxyl, hydroxy(C_{1-3})alkyl, and halo-(C_{1-3})alkyl, e.g., CF_3 , CH_2CF_3 . In preferred embodiments the optional substituents are independently selected from hydroxyl, methoxy, halo, methyl, ethyl, propyl, cyclopropyl, CH_2OH and CF_3 .

The linker group of the organoarsenoxide compounds in accordance with the present invention is a substituted or unsubstituted acetamido group. In one embodiment the linker group is an unsubstituted acetamido group.

In particular, the invention relates to compounds of general formula (I):



20 wherein

the $As(OH)_2$ group may be ortho-, meta- or para- to the N-atom on the phenyl ring;

R^1 is selected from hydrogen and C_{1-3} alkyl;

25 R^2 and R^3 may be the same or different and are independently selected from hydrogen, optionally substituted C_{1-3} alkyl, optionally substituted cyclopropyl, optionally substituted C_{2-3} alkenyl; and optionally substituted C_{1-3} alkoxy;

R^4 and R^5 may be the same or different and are independently selected from hydrogen, optionally substituted C_{1-3} alkyl, optionally substituted cyclopropyl, optionally substituted C_{2-3} alkenyl; and optionally substituted C_{1-3} alkoxy;

5 m is an integer selected from 1, 2 and 3;

n is an integer selected from 1, 2 and 3;

 * indicates a chiral carbon atom; and

 salts and hydrates thereof.

Preferred embodiments of the compounds of general formula (I) are described below. It
10 should be understood that any one or more of the embodiment(s) disclosed herein may be
combined with any other embodiment(s), including preferred embodiment(s).

Optional substituents may be the same or different and are independently selected from
 C_{1-3} alkyl, cyclopropyl, C_{1-3} alkoxy, $-CH_2-(C_{1-3})alkoxy$, C_{6-10} aryl, $-CH_2-phenyl$, halo,
15 hydroxyl, hydroxy(C_{1-3})alkyl, and halo-(C_{1-3})alkyl, e.g., CF_3 , CH_2CF_3 . In one
embodiment the optional substituents are independently selected from hydroxyl, methoxy,
halo, methyl, ethyl, propyl, cyclopropyl, CH_2OH and CF_3 . In one embodiment there are
no optional substituents.

20 The $As(OH)_2$ group may be ortho- or para- to the N-atom on the phenyl ring. In one
embodiment, the $As(OH)_2$ group is para- to the N-atom on the phenyl ring. In another
embodiment the $As(OH)_2$ group is ortho- to the N-atom on the phenyl ring.

R^1 may be hydrogen, methyl or ethyl. In one embodiment R^1 is hydrogen.

25 R^2 and R^3 may be the same or different. R^2 and R^3 may be independently selected from
hydrogen, C_{1-3} alkyl, C_{2-3} alkenyl, C_{1-3} alkoxy, halo(C_{1-3})alkoxy, hydroxy(C_{1-3})alkyl and
halo(C_{1-3})alkyl. In a preferred embodiment R^2 and R^3 may be independently selected
from hydrogen, methyl, ethyl, methoxy, vinyl, CH_2OH , CF_3 and OCF_3 . In another
30 preferred embodiment R^2 and R^3 may be independently selected from hydrogen, methyl
and ethyl. In another embodiment R^2 is methyl and R^3 is hydrogen. In another
embodiment R^2 and R^3 are both hydrogen.

35 R^4 and R^5 may be the same or different. R^4 and R^5 may be independently selected from
hydrogen, C_{1-3} alkyl, C_{2-3} alkenyl, C_{1-3} alkoxy, halo(C_{1-3})alkoxy, hydroxy(C_{1-3})alkyl and

halo-(C₁₋₃)alkyl. In a preferred embodiment R⁴ and R⁵ may be independently selected from hydrogen, methyl, ethyl, methoxy, vinyl, hydroxy(C₁₋₃)alkyl, CF₃ and OCF₃. In another preferred embodiment R⁴ and R⁵ may be independently selected from hydrogen, methyl, ethyl and CH₂OH. In another embodiment R⁴ is methyl or ethyl and R⁵ is 5 hydrogen or methyl. In another embodiment R⁴ is methyl and R⁵ is hydrogen. In another embodiment R⁴ and R⁵ are both hydrogen. In another embodiment R⁴ and R⁵ are both methyl.

10 In one embodiment m is 1 or 2. In another embodiment n is 1 or 2. In another embodiment m and n are both 1.

15 In one embodiment of compounds of formula (I), the As(OH)₂ group is ortho- or para- to the N-atom on the phenyl ring; R¹ is hydrogen or methyl; R² and R³ are independently selected from hydrogen, C₁₋₃ alkyl, C₂₋₃ alkenyl, C₁₋₃ alkoxy, halo-(C₁₋₃)alkoxy, hydroxy(C₁₋₃)alkyl and halo(C₁₋₃)alkyl; R⁴ and R⁵ are independently selected from hydrogen, C₁₋₃ alkyl, C₂₋₃ alkenyl, C₁₋₃ alkoxy, halo(C₁₋₃)alkoxy, hydroxy(C₁₋₃)alkyl and halo(C₁₋₃)alkyl; m is 1 or 2; and n is 1 or 2.


20 In another embodiment of compounds of formula (I), the As(OH)₂ group is ortho- or para- to the N-atom on the phenyl ring; R¹ is hydrogen or methyl; R² and R³ are independently selected from hydrogen, methyl, ethyl, methoxy, vinyl, CH₂OH, CF₃ and OCF₃; R⁴ and R⁵ are independently selected from hydrogen, methyl, ethyl, CH₂OH, methoxy, vinyl, CF₃ and OCF₃; m is 1; and n is 1.

25 In a further embodiment of compounds of formula (I), the As(OH)₂ group is ortho- or para- to the N-atom on the phenyl ring; R¹ is hydrogen or methyl; R² and R³ are independently selected from hydrogen, methyl and ethyl; R⁴ and R⁵ are independently selected from hydrogen, methyl and ethyl; m is 1; and n is 1.

30 In another embodiment of compounds of formula (I), the As(OH)₂ group is ortho- or para- to the N-atom on the phenyl ring; R¹ is hydrogen or methyl; R² is hydrogen or methyl; R³ is hydrogen or methyl; R⁴ is hydrogen, methyl or ethyl; R⁵ is hydrogen or methyl; m is 1; and n is 1.


In another embodiment of compounds of formula (I), the the $\text{As}(\text{OH})_2$ group is para- to the N-atom on the phenyl ring; R^1 is hydrogen; R^2 is hydrogen or methyl; R^3 is hydrogen; R^4 is hydrogen or methyl; R^5 is hydrogen or methyl; m is 1; and n is 1.

5 In a particular embodiment of the invention the compound of formula (I) is:



This compound is referred to herein as “Penicillamine-arsenoxide”.

In another embodiment of the invention the compound of formula (I) is:



10


This compound may be referred to herein as “cysteinyl-phenylarsenoxide”.

Synthesis of Compounds of Formula (I)

Compounds of formula (I) can be readily prepared by those skilled in the art using methods and materials known in the art and with reference to standard text books, such as “Advanced Organic Chemistry” by Jerry March (third edition, 1985, John Wiley and Sons) or “Comprehensive Organic Transformations” by Richard C. Larock (1989, VCH Publishers).

20 A representative scheme for the preparation of compounds of formula (I) is shown below:

Scheme 1



where X is a leaving group and P^1 and P^2 are hydrogen or protecting groups.

In Scheme 1 X is a leaving group capable of being displaced in a nucleophilic reaction by a nucleophile. Suitable leaving groups include halogens, such as iodo, bromo and chloro. Other suitable leaving groups will be known to those skilled in the art. According to the 5 present invention the nucleophilic group may be a thiol. The -SH may be deprotonated by a base, such as sodium hydroxide, potassium hydroxide, sodium hydrogen carbonate, sodium carbonate, etc. The amino group and/or carboxylic acid group may be protected. Suitable protecting groups are known to those skilled in the art and reference may be had to "Protective Groups in Organic Synthesis" by Theodora Greene and Peter Wuts (third 10 edition, 1999, John Wiley and Sons).

In an alternative synthetic strategy, compounds of formula (I) according to the present invention may be prepared by enzymic cleavage of a peptidyl residue of an organo-arsenoxide compound. Suitable enzyme(s) can be selected depending on the composition 15 of the peptidyl residue. Thus, for example, where an organo-arsenoxide starting compound comprises a tripeptide residue such as glutathione, compounds of formula (I) can be prepared by enzymic cleavage of the terminal γ -glutamyl residue with γ -glutamyl transpeptidase (e.g., ovine kidney γ -glutamyl transpeptidase type I), followed by cleavage 20 of the glycanyl residue with an aminopeptidase (e.g., porcine kidney aminopeptidase) to leave a cysteinyl amino acid residue.

The stereochemistry at the chiral atom indicated by * in formula (I) may be (R) or (S). The present invention includes enantiomerically pure forms of compounds of formula (I), mixtures of enantiomers in any ratio, as well as racemates. In one embodiment of the 25 invention the stereochemistry at the chiral atom indicated by * in formula (I) is (R). In another embodiment the invention the stereochemistry at the chiral atom indicated by * in formula (I) is (S).

In another preferred embodiment of the invention the compound of formula (I) is (S)-30 Penicillamine-arsenoxide. In another preferred embodiment of the invention the compound of formula (I) is (R)-Penicillamine-arsenoxide. In another embodiment the compound of formula (I) comprises a mixture of (R) and (S) enantiomers of Penicillamine-arsenoxide. In another embodiment, the mixture of (R) and (S) enantiomers of Penicillamine-arsenoxide is a racemic mixture.

In a preferred embodiment of the invention the compound of formula (I) is (S)-cysteinyl-phenylarsenoxide. In another preferred embodiment of the invention the compound of formula (I) is (R)-cysteinyl-phenylarsenoxide. In another embodiment the compound of formula (I) comprises a mixture of (R) and (S) enantiomers of cysteinyl-phenylarsenoxide. In another embodiment, the mixture of (R) and (S) enantiomers of cysteinyl-phenylarsenoxide is a racemic mixture.

Also included within the scope of the present invention are all stereoisomers, geometric isomers and tautomeric forms of the compounds of formula (I), including compounds exhibiting more than one type of isomerism, and mixtures of one or more thereof. Also included are acid addition or base salts wherein the counterion is optically active, for example, *d*-lactate or *l*-lysine, or racemic, for example, *dl*-tartrate or *dl*-arginine.

Cis/trans (E/Z) isomers may be separated by conventional techniques well known to those skilled in the art, for example, chromatography and fractional crystallisation.

Conventional techniques for the preparation/isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or resolution of the racemate (or the racemate of a salt or derivative) using, for example, chiral high pressure liquid chromatography (HPLC).

Alternatively, the racemate (or a racemic precursor) may be reacted with a suitable optically active compound, for example, an alcohol, or, in the case where the compound of formula I contains an acidic or basic moiety, a base or acid such as 1-phenylethylamine or tartaric acid. The resulting diastereomeric mixture may be separated by chromatography and/or fractional crystallization and one or both of the diastereoisomers converted to the corresponding pure enantiomer(s) by means well known to a skilled person.

Chiral compounds of the invention (and chiral precursors thereof) may be obtained in enantiomerically-enriched form using chromatography, typically HPLC, on an asymmetric resin with a mobile phase consisting of a hydrocarbon, typically heptane or hexane, containing from 0 to 50% by volume of isopropanol, typically from 2% to 20%, and from 0 to 5% by volume of an alkylamine, typically 0.1% diethylamine. Concentration of the eluate affords the enriched mixture.

Therapeutic Application(s)

Compounds of formula (I) in accordance with the present invention, and pharmaceutically acceptable salts and hydrates thereof, are capable of binding to cysteine residues of mitochondrial Adenine Nucleotide Translocator (ANT) in proliferating endothelial cells thereby inducing the Mitochondrial Permeability Transition (MPT). Accordingly, compounds of formula (I) according to the present invention may be used to induce proliferation arrest and cell death. Advantageously, compounds of formula (I) may selectively induce the MPT in proliferating endothelial cells, compared to other cells, such as tumor cells. Compounds of formula (I) may therefore be useful in the treatment of proliferative diseases.

Advantageously, compounds of formula (I), such as Penicillamine-arsenoxide and cysteinyl-phenylarsenoxide, may be more effective than known arsenoxide compounds, including organo-arsenoxide compounds disclosed in WO 01/21628, such as the compound 4-(N-(S-glutathionylacetyl)amino)phenylarsenoxide (“GSAO”), at inhibiting cellular proliferation (particularly proliferation of endothelial cells) and/or reducing the viability of endothelial cells. In the context of this invention, “reducing the viability of endothelial cells” can include cell death, or progression towards cell death. For example, compounds of formula (I) may be about 5-times, about 10-times, about 15-times, about 20-times, about 25-times, about 30-times, about 40-times, about 50-times, about 75-times, or about 100-times more effective than GSAO at inhibiting proliferation of endothelial cells and/or reducing the viability of endothelial cells. In a particular embodiment, compounds of formula (I) are from about 5 to 50-times more effective than GSAO at inhibiting proliferation and/or reducing the viability of endothelial cells. In another embodiment, compounds of formula (I) are from about 10 to 30-times more effective than GSAO at inhibiting proliferation and/or reducing the viability of endothelial cells. In another embodiment, compounds of formula (I) are from about 20 to 25-times more effective than GSAO at inhibiting proliferation and/or reducing the viability of endothelial cells.

Advantageously, compounds of formula (I), such as Penicillamine-arsenoxide and cysteinyl-phenylarsenoxide, may be more efficient than known arsenoxide compounds, for example GSAO, at inducing the Mitochondrial Permeability Transition (MPT). For example, the time for half-maximal swelling of isolated mitochondria may be from about

2 to about 20-times, about 2 to about 15-times, about 2 to about 10-times, about 2 to about 8-times, about 2 to about 6-times, or about 2 to about 4-times faster for compounds of formula (I) compared to other arsenoxide compounds, such as GSAO. In a particular embodiment of the invention compounds of formula (I) are from about 2 to about 10-times faster at inducing the MPT than other arsenoxide compounds, such as GSAO. In another embodiment, compounds of formula (I) are from about 2 to about 6-times faster at inducing the MPT than other arsenoxide compounds, such as GSAO. In another embodiment, compounds of formula (I) are from about 4-times faster at inducing the MPT than other arsenoxide compounds, such as GSAO.

10

The increased efficiency of inhibition of proliferating endothelial cells by compounds of formula (I) according to the present invention may be due to increased accumulation in cells. For example, compounds of formula (I) may accumulate in endothelial cells at a faster rate in comparison to other arsenoxide compounds, such as GSAO. Accordingly, 15 compounds of formula (I) may be more effective inhibitors of cellular proliferation than other organo-arsenoxide compounds, such as GSAO.

20

Thus, another embodiment of the invention relates to a method of treating a cellular proliferative disease in a vertebrate, the method comprising administering to the vertebrate a therapeutically effective amount of at least one compound of formula (I) or a salt or hydrate thereof, or a pharmaceutical composition thereof. The cells may be endothelial cells. Compounds of formula (I) may be selective for proliferating endothelial cells. Compounds of formula (I) may exhibit greater selectivity for proliferating cells than the compound GSAO. The proliferative disease may be cancer, such as solid tumors. 25 Thus, a particular embodiment of the invention relates to a method of treating solid tumors, the method comprising administering to the vertebrate a therapeutically effective amount of at least one compound of formula (I), or a salt or hydrate thereof, or a pharmaceutical composition thereof. In preferred embodiments, the compound of formula (I) may be Penicillamine-arsenoxide or cysteinyl-phenylarsenoxide.

30

In another embodiment the present invention relates to a method of inhibiting angiogenesis in a vertebrate, comprising administering to the vertebrate an effective amount of at least one compound of formula (I) or a salt or hydrate thereof, or a pharmaceutical composition thereof.

35

A further embodiment of the invention relates to a method of selectively inducing the MPT in proliferating cells in a vertebrate comprising administering to the vertebrate a therapeutically effective amount at least one compound of formula (I) or a salt or hydrate thereof, or a pharmaceutical composition thereof. Compounds of formula (I) according to
5 the present invention may induce the MPT by binding to cysteine residues on mitochondrial Adenine Nucleotide Translocator. The compound of formula (I) may be from about 2 to about 20-times, about 2 to about 10-times, about 2 to about 5-times, e.g., about 4-times, more efficient at inducing the MPT in proliferating cells than the compound GSAO.

10

Another embodiment of the invention relates to a method of inducing apoptosis in proliferating cells in a mammal, comprising administering to the mammal an apoptosis-inducing amount of at least one compound of formula (I) or a salt or hydrate thereof, or a pharmaceutical composition thereof. Compounds of formula (I) may selectively induce
15 apoptosis in proliferating cells relative to normal cells. Compounds of formula (I) may be more effective at inducing apoptosis in proliferating cells than the compound GSAO.

20

Compounds of formula (I) according to the present invention also have the potential to be useful for treating acute promyelocytic leukaemia (APL). The current treatment of APL is all-trans retinoic acid (ATRA) therapy that targets the underlying molecular lesion and leads to differentiation of leukaemic blasts into mature granulocytes (Reiter et al., 2004). However, treatment with ATRA is associated with the retinoic acid syndrome which can result in death. Relapse is also a problem. In relapsed patients, arsenic trioxide is considered the treatment of choice (Reiter et al., 2004). However, inorganic arsenicals, such as arsenic trioxide, have several disadvantages when used in therapy. For example, inorganic arsenicals, such as arsenic trioxide, have long been recognised as a poison and carcinogen when present in the body at levels that exceed its capacity to detoxify the metalloid. Arsenic trioxide is administered by intravenous infusion over 2 h to minimize side effects, which include QTc prolongation, APL differentiation syndrome, peripheral neuropathies, hepatic dysfunction and gastrointestinal reactions (Evens et al., 2004). There is a need for safer arsenicals for the treatment of APL, including AML, and myelodysplastic syndrome.

35

Therefore, a further embodiment of the invention relates to a method of treating leukaemia or myelodysplastic syndrome in a vertebrate, comprising administering to the

vertebrate a therapeutically effective amount of at least one compound of formula (I) or a salt or hydrate thereof, or a pharmaceutical composition thereof. In one embodiment the leukaemia is acute promyelocytic leukaemia (APL). In another embodiment the leukaemia is acute myelocytic leukaemia (AML). In accordance with the present invention, compounds of formula (I) may be at least as effective as arsenic trioxide at inhibiting APL cells. In one embodiment, compounds of formula (I) are more effective than arsenic trioxide in treating APL. Advantageously, compounds of formula (I) may exhibit less side effects than arsenic trioxide. Compounds of formula (I) may be more effective than other organoarsenoxide compounds, such as GSAO, in treating APL, AML and/or myelodysplastic syndrome.

Another feature of compounds of formula (I) according to the present invention is that they may have reduced lipid solubility, for example, in comparison to arsenic trioxide. The water solubility of compounds of formula (I) is such that they may have reduced penetration into tissues and be mostly restricted to the intravascular compartment. Therefore, compounds of formula (I) may advantageously may result in less side effects than other arsenicals, such as arsenic trioxide.

Therapeutic advantages may be realised through combination regimens. In combination therapy the respective agents may be administered simultaneously, or sequentially in any order. Accordingly, methods of treatment according to the present invention may involve administration of one or more compounds of formula (I). Compound(s) of formula (I) may be administered in conjunction with conventional therapy, such as radiotherapy, chemotherapy, surgery, or other forms of medical intervention. Examples of 20 chemotherapeutic agents include adriamycin, taxol, fluorouricil, melphalan, cisplatin, oxaliplatin, alpha interferon, vincristine, vinblastine, angioinhibins, TNP-470, pentosan polysulfate, platelet factor 4, angiostatin, LM-609, SU-101, CM-101, Techgalan, thalidomide, SP-PG and the like. Other chemotherapeutic agents include alkylating agents such as nitrogen mustards including mechloethamine, melphan, chlorambucil, 25 cyclophosphamide and ifosfamide, nitrosoureas including carmustine, lomustine, semustine and streptozocin; alkyl sulfonates including busulfan; triazines including dicarbazine; ethylenimines including thiotepa and hexamethylmelamine; folic acid analogues including methotrexate; pyrimidine analogues including 5-fluorouracil, cytosine arabinoside; purine analogues including 6-mercaptopurine and 6-thioguanine; 30 antitumour antibiotics including actinomycin D; the anthracyclines including doxorubicin, 35

bleomycin, mitomycin C and methramycin; hormones and hormone antagonists including tamoxifen and corticosteroids and miscellaneous agents including cisplatin and brequinar, and regimens such as COMP (cyclophosphamide, vincristine, methotrexate and prednisone), etoposide, mBACOD (methotrexate, bleomycin, doxorubicin, 5 cyclophosphamide, vincristine and dexamethasone), and PROMACE/MOPP (prednisone, methotrexate (w/leucovin rescue), doxorubicin, cyclophosphamide, taxol, etoposide/mechlorethamine, vincristine, prednisone and procarbazine).

Pharmaceutical and/or Therapeutic Formulations

10 Typically, for medical use, salts of the compounds of the present invention will be pharmaceutically acceptable salts; although other salts may be used in the preparation of the inventive compounds or of the pharmaceutically acceptable salt thereof. By pharmaceutically acceptable salt it is meant those salts which, within the scope of sound medical judgement, are suitable for use in contact with the tissues of humans and lower 15 animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art.

20 Pharmaceutically acceptable salts of compounds of formula I may be prepared by methods known to those skilled in the art, including for example, (i) by reacting a compound of formula I with the desired acid or base; (ii) by removing an acid- or base-labile protecting group from a suitable precursor of the compound of formula I or by ring-opening a suitable cyclic precursor, for example, a lactone or lactam, using the desired acid or base; or (iii) by converting one salt of the compound of formula I to another by 25 reaction with an appropriate acid or base or by means of a suitable ion exchange column.

30 All three reactions are typically carried out in solution. The resulting salt may precipitate out and be collected by filtration or may be recovered by evaporation of the solvent. The degree of ionisation in the resulting salt may vary from completely ionised to almost non-ionised.

35 Thus, for instance, suitable pharmaceutically acceptable salts of compounds according to the present invention may be prepared by mixing a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, methanesulfonic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, phosphoric acid, acetic acid, oxalic acid, carbonic acid, tartaric

acid, or citric acid with the compounds of the invention. Suitable pharmaceutically acceptable salts of the compounds of the present invention therefore include acid addition salts.

5 S. M. Berge *et al.* describe pharmaceutically acceptable salts in detail in *J. Pharmaceutical Sciences*, 1977, 66:1-19. The salts can be prepared *in situ* during the final isolation and purification of the compounds of the invention, or separately by reacting the free base function with a suitable organic acid. Representative acid addition salts include acetate, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, 10 borate, butyrate, camphorate, camphorsulfonate, citrate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptonate, glycerophosphate, hemisulfate, heptonate, hexanoate, hydrobromide, hydrochloride, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, 15 oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, toluenesulfonate, undecanoate, valerate salts, and the like. Representative alkali or alkaline earth metal salts include sodium, lithium potassium, calcium, magnesium, and the like, as well as non-toxic ammonium, quaternary ammonium, and amine cations, 20 including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, triethanolamine and the like.

Convenient modes of administration include injection (subcutaneous, intravenous, etc.), 25 oral administration, inhalation, transdermal application, topical creams or gels or powders, or rectal administration. In one embodiment, the mode of administration is parenteral. In another embodiment, the mode of administration is oral. Depending on the route of administration, the formulation and/or compound may be coated with a material to protect the compound from the action of enzymes, acids and other natural conditions 30 which may inactivate the therapeutic activity of the compound. The compound also may be administered parenterally or intraperitoneally.

Dispersions of compounds according to the invention may also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions

of storage and use, pharmaceutical preparations may contain a preservative to prevent the growth of microorganisms.

Pharmaceutical compositions suitable for injection include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. Ideally, the composition is stable under the conditions of manufacture and storage and may include a preservative to stabilise the composition against the contaminating action of microorganisms such as bacteria and fungi.

10

The compound(s) of the invention may be administered orally, for example, with an inert diluent or an assimilable edible carrier. The compound(s) and other ingredients may also be enclosed in a hard or soft shell gelatin capsule, compressed into tablets, or incorporated directly into an individual's diet. For oral therapeutic administration, the compound(s) may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Suitably, such compositions and preparations may contain at least 1% by weight of active compound. The percentage of the compound(s) of formula (I) in pharmaceutical compositions and preparations may, of course, be varied and, for example, may conveniently range from about 2% to about 90%, about 5% to about 80%, about 10% to about 75%, about 15% to about 65%; about 20% to about 60%, about 25% to about 50%, about 30% to about 45%, or about 35% to about 45%, of the weight of the dosage unit. The amount of compound in therapeutically useful compositions is such that a suitable dosage will be obtained.

25

The language "pharmaceutically acceptable carrier" is intended to include solvents, dispersion media, coatings, anti-bacterial and anti-fungal agents, isotonic and absorption delaying agents, and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the compound, use thereof in the therapeutic compositions and methods of treatment and prophylaxis is contemplated. Supplementary active compounds may also be incorporated into the compositions according to the present invention. It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. "Dosage unit form" as used herein refers to physically discrete units suited as unitary dosages for the individual to be treated; each

unit containing a predetermined quantity of compound(s) is calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The compound(s) may be formulated for convenient and effective administration in effective amounts with a suitable pharmaceutically acceptable carrier in an acceptable dosage unit.

5 In the case of compositions containing supplementary active ingredients, the dosages are determined by reference to the usual dose and manner of administration of the said ingredients.

In one embodiment, the carrier is an orally administrable carrier.

10

Another form of a pharmaceutical composition is a dosage form formulated as enterically coated granules, tablets or capsules suitable for oral administration.

Also included in the scope of this invention are delayed release formulations.

15

Compounds of formula (I) according to the invention also may be administered in the form of a "prodrug". A prodrug is an inactive form of a compound which is transformed *in vivo* to the active form. Suitable prodrugs include esters, phosphonate esters etc, of the active form of the compound.

20

In one embodiment, the compound of formula (I) may be administered by injection. In the case of injectable solutions, the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable

25 oils. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by including various anti-bacterial and/or anti-fungal agents. Suitable agents are well known to those skilled in the art and include, for example, parabens, chlorobutanol, phenol,

30 benzyl alcohol, ascorbic acid, thimerosal, and the like. In many cases, it may be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminium monostearate and gelatin.

35

Sterile injectable solutions can be prepared by incorporating the analogue in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilisation. Generally, dispersions are prepared by incorporating the analogue into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above.

Tablets, troches, pills, capsules and the like can also contain the following: a binder such as gum gragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin or a flavouring agent such as peppermint, oil of wintergreen, or cherry flavouring. When the dosage unit form is a capsule, it can contain, in addition to materials of the above type, a liquid carrier. Various other materials can be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills, or capsules can be coated with shellac, sugar or both. A syrup or elixir can contain the analogue, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavouring such as cherry or orange flavour. Of course, any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed. In addition, the analogue can be incorporated into sustained-release preparations and formulations.

Preferably, the pharmaceutical composition may further include a suitable buffer to minimise acid hydrolysis. Suitable buffer agent agents are well known to those skilled in the art and include, but are not limited to, phosphates, citrates, carbonates and mixtures thereof.

Single or multiple administrations of the compounds and/or pharmaceutical compositions according to the invention may be carried out. One skilled in the art would be able, by routine experimentation, to determine effective, non-toxic dosage levels of the compound and/or composition of the invention and an administration pattern which would be suitable for treating the diseases and/or infections to which the compounds and compositions are applicable.

Further, it will be apparent to one of ordinary skill in the art that the optimal course of treatment, such as the number of doses of the compound or composition of the invention

given per day for a defined number of days, can be ascertained using convention course of treatment determination tests.

Generally, an effective dosage per 24 hours may be in the range of about 0.0001 mg to 5 about 1000 mg per kg body weight; for example, about 0.001 mg to about 750 mg per kg body weight; about 0.01 mg to about 500 mg per kg body weight; about 0.1 mg to about 500 mg per kg body weight; about 0.1 mg to about 250 mg per kg body weight; or about 1.0 mg to about 250 mg per kg body weight. More suitably, an effective dosage per 24 hours may be in the range of about 1.0 mg to about 200 mg per kg body weight; about 1.0 10 mg to about 100 mg per kg body weight; about 1.0 mg to about 50 mg per kg body weight; about 1.0 mg to about 25 mg per kg body weight; about 5.0 mg to about 50 mg per kg body weight; about 5.0 mg to about 20 mg per kg body weight; or about 5.0 mg to about 15 mg per kg body weight.

15 Alternatively, an effective dosage may be up to about 500mg/m². For example, generally, an effective dosage is expected to be in the range of about 25 to about 500mg/m², about 25 to about 350mg/m², about 25 to about 300mg/m², about 25 to about 250mg/m², about 50 to about 250mg/m², and about 75 to about 150mg/m².

20 In another embodiment, a compound of Formula (I) may be administered in an amount in the range from about 100 to about 1000 mg per day, for example, about 200 mg to about 750 mg per day, about 250 to about 500 mg per day, about 250 to about 300 mg per day, or about 270 mg to about 280 mg per day.

25 Compounds in accordance with the present invention may be administered as part of a therapeutic regimen with other drugs. It may desirable to administer a combination of active compounds, for example, for the purpose of treating a particular disease or condition. Accordingly, it is within the scope of the present invention that two or more pharmaceutical compositions, at least one of which contains a compound of formula (I) 30 according to the present invention, may be combined in the form of a kit suitable for co-administration of the compositions.

The invention will now be described in more detail, by way of illustration only, with respect to the following examples. The examples are intended to serve to illustrate this

invention and should not be construed as limiting the generality of the disclosure of the description throughout this specification.

Examples

5 **EXAMPLE 1 – Preparation and Efficacy of (S)-Penicillamine-Arsenoxide (“PENAO”)**

Materials and Methods

Synthesis and purification of (S)-Penicillamine-arsenoxide:

p-Arsanilic acid (10 g, 46.07 mmol) was dissolved in a 1.18 M Na₂CO₃ solution, made from Na₂CO₃ (15 g, 141.5 mmol) dissolved in H₂O (120 mL) in a 500 mL round-bottom flask. The solution was cooled in a 4 °C fridge for 2 hours and then placed in an ice bath upon a magnetic stirrer. A solution of bromoacetyl bromide (9 mL, 101.4 mmol) in CH₂Cl₂ (14 mL) was added in 4 aliquots to the flask while the mixture was vigorously stirred. Addition took about 1 min with CO₂ evolution. The mixture was allowed to stir in the ice-bath for 5 min, and then at room temperature for 30 min till CO₂ evolution ceased. The mixture was decanted into a 250 mL separatory funnel. Additional CH₂Cl₂ (10 mL) was added and the layers were allowed to separate for about 10 min. The CH₂Cl₂ layer was separated and the aqueous layer was placed in a 400 mL beaker. The solution was stirred and acidified with 98% H₂SO₄ (2.8 mL) to pH 4. A white precipitate resulted which was collected by filtration (14.83 g, 95% yield). The resulting 4-(2-bromoacetylamino)benzenearsonic acid (“BRAO”) (14.83g, 43.88 mmol) was dissolved in 1:1 HBr/MeOH (210 mL) in a 500 mL 3-neck round bottom flask. NaI (5 mg) was added and the mixture was stirred. SO₂ was bubbled through at ca. 2 bubbles/second and after 10 min a white precipitate started to form. SO₂ was bubbled through for a further 20 h and the mixture was stirred at a medium speed. The solid was collected by filtration, washed with the filtrate then water (30 mL x 3), and placed on the rotary evaporator at 50 °C for 5 h to give 4-(2-bromoacetylamino)benzenearsonous acid (6.04g, 38.8% yield). A portion of the 4-(2-bromoacetylamino)benzenearsonous acid (500 mg, 1.553 mmol) was dissolved in nitrogen-flushed DMSO (10 mL) and added drop-wise over about 1 min to an solution of S-penicillamine (265 mg, 1.77 mmol) in an aqueous NaHCO₃ solution (840 mg, 10 mmol) which used nitrogen-saturated H₂O (20 mL). The addition took place in a 100 mL round-bottom flask and the clear solution was stirred on a low speed under argon for 4 h. The solution was acidified with 98% H₂SO₄ (about 0.2 mL) to pH 5. Acetone (500 mL) was stirred vigorously, and the acidified solution was added drop-wise over

about 5 min to yield a white precipitate. The supernatant was centrifuged, decanted, and the resulting white solid was further washed and re-centrifuged with acetone (20 mL x 2), transferred with acetone (40 mL) into a 100 mL pear-shaped flask and dried on the rotary evaporator at 25 °C for 2 h. Crude Penicillamine-arsenoxide was found to be about 30%
5 pure by internal standard ¹H-NMR.

Crude (S)-Penicillamine-arsenoxide (100.2 mg, 0.077 mmol as 30% pure) was dissolved in nitrogen-saturated H₂O (2.5 mL) and purified on a Low Pressure Liquid Chromatography system. The conditions used were a 30 cm column with a 1.25 cm
10 internal radius, nitrogen-saturated H₂O as the running buffer, Biogel P-2 resin and a rate of 0.25mL/min. The second peak was collected in a 50 mL Falcon tube, frozen in liquid N₂, freeze-dried for 3 days, and placed in a desiccator for 1 day to yield dried pure (S)-Penicillamine-arsenoxide (20.3 mg, 0.052 mmol). The process was repeated with more portions of crude Penicillamine-arsenoxide (696 mg in total) and this yielded purified (S)-
15 Penicillamine-arsenoxide (114 mg, 26.5% yield). The structure of (S)-Penicillamine-arsenoxide (Fig. 1) was confirmed by MS, ¹H-NMR and 2D NMR. The purity obtained was 90% by an arsenical activity assay. The main impurity was water as the final product is extremely hygroscopic. The molecular weight of (S)-Penicillamine-arsenoxide is 390.28 g/mole.

20 ¹H-NMR (300 MHz, D₂O): δ 1.32(s, 3H), 1.53(s, 3H), 3.55(d, J=3.4Hz, 2H), 3.63 (s, 1H), 7.52(d, J=8.3Hz, 2H), 7.68(d, J=8.3Hz, 2H). The proton NMR spectrum (Fig. 2) was recorded on a Bruker, dual channel probe NMR spectrometer. Rapid keto-enol tautomerism and subsequent deuterium replacement results in the loss of the doublet peak
25 at δ 3.5518 which occurs over 1h. This can be monitored using time-dependant NMR.

¹³C-NMR (D₂O): δ 23.15, 26.83, 33.12, 46.75, 61.36, 121.62, 130.04, 139, 144, 170.

30 The structure of (S)-Penicillamine-arsenoxide was also confirmed by an HMBC experiment (2D ¹H-¹³C multiple bond coupling, see Fig 3).

MS: *m/z* 413.011678 (M+Na)⁺ (C₁₃H₁₉SO₅N₂AsNa requires 413.012285). (Fig 4)

Synthesis of Penicillamine-arsonic acid

p-Arsanilic acid (10 g, 46.07 mmol) was dissolved in a 1.18 M Na₂CO₃ solution, made from Na₂CO₃ (15 g, 141.5 mmol) dissolved in H₂O (120 mL) in a 500 mL round-bottom flask. The solution was cooled in a 4 °C fridge for 2 hours and then placed in an ice bath 5 upon a magnetic stirrer. A solution of bromoacetyl bromide (9 mL, 101.4 mmol) in CH₂Cl₂ (14 mL) was added in 4 aliquots to the flask while the mixture was vigorously stirred. Addition took about 1 min with CO₂ evolution. The mixture was allowed to stir in the ice-bath for 5 min, and then at room temperature for 30 min till CO₂ evolution ceased. The mixture was decanted into a 250 mL separatory funnel. Additional CH₂Cl₂ 10 (10 mL) was added and the layers were allowed to separate for about 10 min. The CH₂Cl₂ layer was separated and the aqueous layer was placed in a 400 mL beaker. The solution was stirred and acidified with 98% H₂SO₄ (2.8 mL) to pH 4. The resulting white precipitate 4-(2-bromoacetylamino)benzenearsonic acid ("BRAO") was collected by filtration (14.83 g, 95% yield).

15 A portion of 4-(2-bromoacetylamino)benzenearsonic acid (500 mg, 1.479 mmol) was dissolved in aqueous NaHCO₃ solution (420 mg, 4.999 mmol) in H₂O (10 mL) and added drop-wise over about 1 min to a solution of (S)-penicillamine (265 mg, 1.77 mmol) in an aqueous NaHCO₃ solution (640 mg, 7.618 mmol) in H₂O (15 mL). The addition took 20 place in a 100 mL round-bottom flask and the clear solution was stirred on a low speed for 4 h. The solution was acidified with 98% H₂SO₄ (about 0.25 mL) to pH 5. A 1:1 acetone:ethanol (500 mL) solution was stirred vigorously, and the acidified solution was added drop-wise over about 5 min to yield a white precipitate. The supernatant was centrifuged, which was decanted, and the resulting white solid was further washed and re- 25 centrifuged with 1:1 acetone:ethanol (25 mL x 2), transferred with 1:1 acetone:ethanol (50 mL) into a 100 mL pear-shaped flask and dried on the rotary evaporator at 25 °C for 2 h. The resulting (S)-Penicillamine-arsonic acid was found to be about 44% pure by internal standard ¹H-NMR spectroscopy and was used without further purification (1.022 g, 75% yield). The structure of (S)-Penicillamine-arsonic acid was confirmed by MS, ¹H- 30 NMR and 2D NMR. The main impurity was water as the final product is extremely hygroscopic. The molecular weight is 406.28 g/mole.

GSAO was prepared as previously described (Don et al., 2003).

A 1 M solution of arsenic trioxide was prepared by dissolving the solid (Sigma, St. Louis, MO) in 3 M NaOH prepared in deoxygenated water. The solution was diluted 10-fold in deoxygenated water, the pH adjusted to 7.0 using HCl and stored at 4°C in an airtight container until use.

5

Arsenical assay

(S)-Penicillamine-arsenoxide was dissolved in the titration buffer, sterile filtered, and the concentration determined by titrating with dimercaptopropanol and calculating the remaining free thiols with 5,5'-dithiobis(2-nitrobenzoic acid). The solution was stored at 10 4°C in the dark until use. There was no significant loss in the active concentration of stock solutions of the arsenicals for at least a month when stored under these conditions.

Mitochondrial swelling assay

Mitochondria were isolated from the livers of ~250 g male Wistar rats using differential 15 centrifugation as previously described (Dilda et al., 2005a; Don et al., 2003). The final mitochondrial pellet was resuspended in 3 mM HEPES-KOH, pH 7.0 buffer containing 213 mM mannitol, 71 mM sucrose and 10 mM sodium succinate at a concentration of 30 mg of protein per mL. Mitochondrial permeability transition induction was assessed spectrophotometrically by suspending the liver mitochondria at 0.5 mg of protein per mL 20 at 25°C in 3 mM HEPES-KOH, pH 7.0 buffer containing 75 mM mannitol, 250 mM sucrose, 10 mM sodium succinate, and 2 µM rotenone. Swelling was measured by monitoring the associated decrease in light scattering at 520 nm using a SpectraMax Plus microplate reader (Molecular Devices, Palo Alto, CA).

25 Cell culture

BAE cells were from Cell Applications, San Diego, CA and BxPC-3, HT1080, LLC, PANC-1, MCF-7, HCT116 and K562 cells were from ATCC, Bethesda, MD. NB4 and MDCK2 cells were from Shane Supple (Kanematsu Laboratories, Royal Prince Alfred Hospital, Sydney, Australia) and P. Borst (The Netherlands Cancer Institute, Amsterdam, 30 The Netherlands). BAE, HT1080, Panc-1, MCF-7, HCT116, MDCK2 and LLC cells were cultured in DMEM. NB4, K562 and BxPC-3 cells were cultured in RPMI medium. The cells were supplemented with 10% foetal calf serum (FBS), 2 mM L-glutamine, and 1 U.mL⁻¹ penicillin/streptomycin. Cell culture plasticware was from Techno Plastic Products (Trasadingen, Switzerland). All other cell culture reagents were from Gibco 35 (Gaithersburg, MD).

Cell proliferation and viability assays.

BAE, NB4, K562, MDCK2, HT1080, LLC, HCT116, Panc-1, MCF-7 and BxPC-3 cells were seeded at a density of 1.5×10^3 , 3×10^3 , 4×10^3 , 5×10^2 , 2×10^3 , 5×10^2 , 5×10^2 , 6×10^3 , 6×10^3 and 1×10^4 cells per well, respectively, into 96-well plates. Adherent cells were allowed to adhere overnight. They were then cultured for 72 h in medium containing 10% fetal calf serum and (S)-Penicillamine-arsenoxide. Viable cells were determined by incubating cells with the tetrazolium salt MTT (Sigma, St. Louis, MO), which is metabolized by viable cells to form insoluble purple formazan crystals. DMSO was added to lyse cells, the contents of the wells were homogenized and the absorbance measured at 550 nm. Cell number in the untreated control was normalized as 100%, and viable cell number for all treatments was expressed as percentage of control. The cytotoxic effects of (S)-Penicillamine-arsenoxide were assayed by flow cytometry with propidium iodide. BAE cells were seeded at a density of 5×10^4 cells per well into 12-well plates, allowed to adhere overnight, then treated for 48 h with GSAO. Adherent cells were detached with trypsin/EDTA and combined with the growth medium containing the cells that had detached during treatment. The combined cells were pelleted, resuspended in 0.5 mL serum-free medium containing $1 \mu\text{g.mL}^{-1}$ propidium iodide (Molecular Probes, Eugene, OR) and analysed by flow cytometry.

20

Flux of (S)-Penicillamine-arsenoxide.

BAE cells were seeded at a density of 1.5×10^6 cells in Petri dishes and allowed to adhere overnight. Cells were incubated with 50 μM (S)-Penicillamine-arsenoxide at discrete times for up to 2 h at 37°C and then washed three times with ice-cold PBS. The washed cells were lysed in 1 mL of 70% w/w nitric acid. Petri dishes were then washed twice with 1 mL of PBS and kept at 4°C until use. Samples were diluted 10-fold and analysed for arsenic atoms using an Elan 6100 Inductively Coupled Plasma Spectrometer (Perkin Elmer Sciex Instruments, Shelton, CT).

30

Organic Anion Transporting Polypeptide (OATP) studies. 750,000 BAE cells were seeded in 6 well plates containing DMEM with 10% fetal calf serum and allowed to adhere overnight. Cells were pretreated or not with 500 μM 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid (DIDS) for 30 min and then incubated with 20 μM (S)-Penicillamine arsenoxide for 2 h at 37°C and 5% CO₂. Cells were then washed twice with ice-cold PBS and lysed with 70% nitric acid. Cellular arsenic levels were determined by ICPMS.

35

5000 BAE cells were seeded in 96 well plates containing DMEM with 10% fetal calf serum and allowed to adhere overnight. Cells were pretreated or not with 300 μ M DIDS for 30 min and then incubated with 1.5 μ M (S)-Penicillamine arsenoxide for 24 h at 37°C
5 and 5% CO₂. Cell viability was determined using MTT.

10 Drug transporter transfectants. Transfectants of the Madin-Darby canine kidney II (MDCKII) polarised epithelial cell line, over-expressing multidrug resistance-associated proteins (MRP) 1, 2 or 3, have been described (Evers et al., 2000; Kool et al., 1999), as have the MEF/MDR1 clone H4 over-expressing human MDR1 or BCRP (Dilda et al., 2005b). Cells were grown and maintained as adherent monolayers in DMEM containing 10% calf serum (CosmicTM, Hyclone, Tauranga, New Zealand), 100 μ g.mL⁻¹ penicillin and 60 μ g.mL⁻¹ streptomycin. Cytotoxicity assays were performed as described previously (Allen et al., 1999).

15 Primary tumor growth assays. Female 7 to 9 week old Balb C nude mice were used (UNSW Biological Resource Centre). Mice were held in groups of 3 to 5 at a 12 h day and night cycle and were given animal chow and water *ad libidum*. A suspension of 2 x 10⁶ BxPC-3 cells in 0.2 mL of PBS was injected subcutaneously in the proximal midline.
20 Tumors were allowed to establish and grow to a size of ~50 mm³ after which they were randomized into four groups. Tumor volume was calculated using the relationship length \times height \times width \times 0.523. Tumor doubling time (T_D) was calculated from the tumor growth rate curve during exponential growth using the formula T_D = 0.693/ln(V_F/V_I), where V_F is final tumor volume and V_I is initial tumor volume (Wolff et al., 2004).
25 Animals were implanted with 28 day alzet model 1004 micro-osmotic pumps (ALZA Corporation, Palo Alto, CA) subcutaneously in the flank. The pumps delivery 0.25, 0.5 or 1 mg/kg/day (S)-Penicillamine arsenoxide in 100 mM glycine. Tumor volume and animal weight was measured every 2 or 3 days.

30 Statistical analyses.

Results are presented as means \pm SD. All tests of statistical significance were two-sided, and P values < 0.05 were considered statistically significant.

Results and Discussion

(S)-Penicillamine-arsenoxide inhibits proliferation of mammalian cells

Reported IC₅₀ values for proliferation arrest and loss of viability of bovine aortic endothelial cells (BAE) cells induced by GSAO are 10 µM and 75 µM, respectively (Dilda et al., 2005a; Don et al., 2003). The IC₅₀ for proliferation arrest of BAE cells is 0.4 µM for (S)-Penicillamine-arsenoxide (Fig. 5) compared to 10 µM for GSAO, while the IC₅₀ value for loss of viability is 3.5 µM (Fig. 6). (S)-Penicillamine-arsenoxide, therefore, is ~25-times more effective than GSAO at blocking proliferation and reducing the viability of endothelial cells.

10

(S)-Penicillamine-arsenoxide is a selective inhibitor of endothelial cells compared to tumour cells. Comparison of the IC₅₀ for proliferation arrest of endothelial and epithelial cells compared to eight different tumour cell lines is shown in Table 1. All tumour cells tested were 1.6 to 30-fold more resistant to (S)-Penicillamine-arsenoxide than endothelial cells. BAE cells were also 5.6-fold more sensitive to (S)-Penicillamine-arsenoxide than kidney epithelial cells. (S)-Penicillamine-arsenoxide is equivalent to arsenic trioxide in its effects on APL cells, while GSAO is ~10-fold less active (Fig. 7).

Table 1. (S)-Penicillamine-arsenoxide IC₅₀ values for proliferation arrest for various cell lines.

Cell Type	Cell Line	IC ₅₀ , µM
bovine aortic endothelial	BAEC	0.43
human acute promyelocytic leukaemia	NB4	0.70
human chronic myelogenous leukaemia	K562	1.4
dog kidney epithelial	MDCK2	2.4
human fibrosarcoma	HT1080	4.0
human lung carcinoma	LLC	5.0
human colorectal carcinoma	HCT1116	6.0
human pancreatic carcinoma	PANC-1	6.5
human mammary carcinoma	MCF-7	9.0
human pancreatic carcinoma	BxPC-3	13

(S)-Penicillamine-arsenoxide is also more efficient than GSAO at inducing the mitochondrial permeability transition. (S)-Penicillamine-arsenoxide, like GSAO,

triggered swelling of isolated rat liver mitochondria in a time- and concentration-dependent manner (Fig. 8). The time for half-maximal swelling of isolated mitochondria was approximately 4 times faster for (S)-Penicillamine-arsenoxide compared to GSAO.

5 Without intending to be bound by any particular theory, a possible mechanism for the increased anti-proliferative activity of (S)-Penicillamine-arsenoxide compared to GSAO was increased accumulation in cells. This theory was tested by comparing the uptake of the two compounds in endothelial cells by measuring cellular accumulation of arsenic. (S)-Penicillamine-arsenoxide accumulated in BAE cells at an approximately 70-fold 10 faster rate than GSAO (Fig. 9). The initial rates of accumulation of GSAO and (S)-Penicillamine-arsenoxide were 1 and 69 pmol per 10^6 cells per min, respectively.

OATP is involved in (S)-Penicillamine transport across the plasma membrane

15 DIDS is an inhibitor of the plasma membrane organic anion transporting polypeptide (OATP) (Kobayashi et al., 2003). The finding that this compound inhibits (S)-Penicillamine arsenoxide uptake (Fig 10A) and reduces its anti-proliferative activity (Fig, 10B) in BAE cells implies that this transporter is involved in (S)-Penicillamine arsenoxide uptake into these cells.

20 (S)-Penicillamine arsenoxide is exported from the cell by MRP1 and 2
MRP1/2 mediates export of GSAO from BAE cells (Dilda et al., 2005b). Penicillamine-arsenoxide is also a substrate for MRP1/2. More (S)-Penicillamine-arsenoxide accumulated in BAE cells in the presence of the MRP1/2 inhibitors 4H10 and MK-571 25 (Fig. 11A), which correlated with more potent anti-proliferative effect (Fig. 11B). The inhibitors alone had no effect on BAE cell proliferation (data not shown).

30 Mammalian cells over-expressing MRP1, 2, 3 or 6, or MDR1 or BCRP were tested for resistance to (S)-Penicillamine-arsenoxide. MRP1, MRP2 or MRP3 was over-expressed in the canine kidney epithelial MDCKII cell line, while MRP6, MDR1 or BCRP was over-expressed in the murine embryo fibroblast MEF3.8 line. Cells were exposed to the indicated concentrations of (S)-Penicillamine-arsenoxide for 96 h and the number of viable cells measured and expressed relative to the number of untreated cells. Resistance factor is calculated relative to the (S)-Penicillamine arsenoxide IC_{50} for proliferation arrest of non-transfected parental cells.

Table 2. Resistance of mammalian cells over-expressing different drug transporters to (S)-Penicillamine-arsenoxide.

Transporter	Resistance Factor
MD/MRP1	3.7
MD/MRP2	4.6
MD/MRP3	0.8
MEF/MRP6	1.3
MEF/MDR1	1.2
MEF/BCRP	1.1

5 These results indicate that both GSAO and (S)-Penicillamine-arsenoxide are exported from BAE cells by MRP1/2.

Treatment of BAE cells with glutathione reduced GSAO inhibition of BAE cell proliferation, while blocking *de novo* synthesis of glutathione with buthionine 10 sulfoximine (BSO), an inhibitor of the γ -glutamyl cysteine synthase, enhanced the proliferation arrest by almost 100-fold (Dilda et al., 2005b). These results indicated that MRP1/2 requires cellular glutathione for efficient transport of GSAO from the cell. Similar to the findings with GSAO, treating BAE cells with BSO enhanced the (S)-Penicillamine-arsenoxide IC₅₀ for proliferation arrest by approximately 25-fold (Fig. 12).

15 These results indicate that (S)-Penicillamine-arsenoxide is a more effective inhibitor of endothelial cells because it accumulates in the cells at a much faster rate than GSAO.

Anti-tumour activity of (S)-Penicillamine arsenoxide

20 BalbC nude mice bearing subcutaneous human BxPC-3 pancreatic carcinoma tumours in the proximal midline were implanted with 28 day micro-osmotic alzet pumps subcutaneously in the flank. The pumps delivered 0.25, 0.5 or 1 mg per kg per day (S)-Penicillamine arsenoxide. The growth of the BxPC-3 tumours was significantly inhibited in the mice receiving (S)-Penicillamine arsenoxide (Fig. 13). The tumour doubling times 25 are 9.2, 8.3, 13.9 and 16.2 days for groups treated with vehicle (100 mM glycine) or 0.25, 0.5 and 1 mg/kg/day (S)-Penicillamine arsenoxide, respectively.

There was no change in the weight of the vehicle- versus (S)-Penicillamine arsenoxide-treated animals (not shown). There was some skin toxicity at the pump delivery site in the highest dose animals. There was skin necrosis at the delivery site in 3 of the 10 mice and in 1 mouse there was an accumulation of connective tissue. There was some 5 evidence of accumulation of connective tissue at the delivery site in the occasional mouse at the lower doses of (S)-Penicillamine arsenoxide.

EXAMPLE 2 – Preparation and Efficacy of 4-(N-(S-Cysteinylacetyl)amino)-phenylarsinous acid (“CAO”)

10

Materials and Methods

Cell proliferation assay

Bovine aortic endothelial (BAE) cells were from Cell Application (San Diego, CA). BAE cells were cultured in DMEM supplemented with 10% fetal calf serum, 2 mM L-glutamine, and 5 units per mL penicillin and streptomycin (Gibco, Gaithersburg, MD). Cells were cultured at 37°C in a 5% CO₂, 95% air atmosphere. BAE cells were seeded in 96-well plates (5,000 cells per well) in 0.2 ml of culture medium. After 24 h of growth, the medium was replaced with fresh culture medium supplemented with GSAO, CAO or 4H10 and cells were cultured for an additional 24, 48 or 72 h. Viable attached cells were 15 determined using the tetrazolium salt MTT (Sigma, St. Louis, MO) according to the manufacturer's protocol. Results were expressed as percentage of untreated controls. 20

Preparation of CAO

GSAO was produced as described previously (WO 01/21628) to a purity >94% by HPLC. 25 A 50 mM solution of GSAO was made by dissolving solid in 20 mM Hepes, pH 7.0 buffer containing 0.14 M NaCl, 20 mM glycine and 1 mM EDTA. 4-(N-(S-cysteinylglycylacetyl)amino)phenylarsinous acid was produced by cleaving the γ-glutamyl group from GSAO with ovine kidney γ-glutamyl transpeptidase type I (Sigma, product number G8040) (Fig. 14). A 10 mM solution of GSAO was incubated with 0.55 30 units per ml γGT in 15 mM Tris, pH 7.4 buffer containing 40 mM glycyl-glycine for 1 h at 30°C. The γGT was removed from the reaction by filtration using a YM3 Microcon membrane (Millipore, Billerica, MA).

4-(N-(S-cysteinylacetyl)amino)phenylarsinous acid (CAO) was produced by cleaving the 35 glycine amino acid from 4-(N-(S-cysteinylglycylacetyl)amino)phenylarsinous acid with

porcine kidney aminopeptidase N (Type IV-S, Sigma, product number L5006) (Fig. 14). The filtrate was incubated with 2 units per ml aminopeptidase N for 1 h at 37°C. The aminopeptidase N was removed from the reaction by filtration using a YM3 Microcon membrane (Millipore). The concentration of CAO was measured by titrating with 5 dimercaptopropanol and calculating the remaining free thiols with 5,5'-dithiobis(2-nitrobenzoic acid) (Don et al., 2003). The titrated solutions were sterile filtered and stored at 4°C in the dark until use.

HPLC analysis

10 GSAO and CAO were characterized by HPLC (1200 Series; Agilent Technologies, Santa Clara, CA). Samples were resolved on a Zorbax Eclipse XDB-C18 column (4.6 x 150 mm, 5 μ m; Agilent Technologies) using a mobile phase of acetonitrile-water (25:75 vol/vol), flow rate of 0.5 ml.min⁻¹ and detection by absorbance at 256 nm (Fig. 15).

15 Accumulation of GSAO and CAO in BAE cells

Depending on the type of experiments, 1.6 x10⁶ or 7.5 x10⁵ BAE cells were seeded in petri dishes or 6-well-plates, respectively, and allowed to attach overnight. The medium was replaced and the cells were incubated for 30 min in the absence or presence of acivicin or 4H10. The cells were then incubated with 50 or 100 μ M GSAO or CAO for 20 30 min for 4 h. Cells were then washed twice with ice-cold PBS and lysed with 1 ml of 70% w/w nitric acid. Lysates were diluted 30-fold and analyzed for arsenic atoms using an Elan 6100 Inductively Coupled Plasma Spectrometer (Perkin Elmer Sciex Instruments, Shelton, CT).

25 Mitochondrial swelling assay. Mitochondria were isolated from the livers of ~20 g female BalbC nude mice using differential centrifugation as described previously (Dilda et al., 2005a). The final mitochondrial pellet was resuspended in 3 mM Hepes-KOH, pH 7.0 buffer containing 213 mM mannitol, 71 mM sucrose and 10 mM sodium succinate at a concentration of 30 mg of protein per mL. Mitochondrial permeability transition induction was assessed spectrophotometrically by suspending the liver mitochondria at 1 mg of protein per ml at 37°C in 3 mM Hepes-KOH, pH 7.0 buffer containing 75 mM mannitol, 250 mM sucrose, 10 mM sodium succinate, and 2 mM rotenone (Dilda et al., 30 2005a). Swelling was measured by monitoring the associated decrease in light scattering at 520 nm using a Molecular Devices M2 Microplate Reader (Palo Alto, CA).

Results and Discussion

CAO accumulates more rapidly in cells and have greater anti-proliferative activity than GSAO.

4-(N-(S-cysteinylacetyl)amino)phenylarsinous acid (CAO) was produced by enzymatic 5 cleavage of GSAO and its accumulation in endothelial cells and effects on cell proliferation was measured. 4-(N-(S-cysteinylglycylacetyl)amino)-phenylarsinous acid was produced by cleaving the γ -glutamyl group from GSAO with ovine kidney γ -glutamyl transpeptidase, and 4-(N-(S-cysteinylacetyl)amino)-phenylarsinous acid (CAO) was produced by cleaving the glycine amino acid from this intermediate with porcine 10 kidney aminopeptidase N (Fig. 14). The enzymes were removed from the reactions by size-exclusion filtration.

CAO accumulated in endothelial cells at a ~8-fold faster rate than GSAO (Fig. 16A). Cellular accumulation of these metabolites is a balance between rate of uptake and rate of 15 export from the cell. GSAO accumulation in cells is controlled by rate of export by the multidrug resistance-associated proteins (MRP) 1 and 2 (Dilda et al., 2005b). To test whether CAO is also exported by MRP, the effect of the MRP-1 inhibitor, 4H10, on accumulation in endothelial cells was measured. Cellular accumulation of CAO was increased ~3-fold, respectively, when MRP-1 was inhibited (Fig. 16B). This finding 20 implies that the increased accumulation of CAO in endothelial cells is predominantly due to increased rate of uptake.

The faster rate of accumulation of CAO in endothelial cells was anticipated to result in increased anti-proliferative activity. The IC₅₀'s for proliferation arrest of endothelial cells 25 by GSAO and CAO in 24, 48 and 72 h assays is shown in Fig. 16C. It is clear from the results that the IC₅₀ for GSAO markedly decreases with time of incubation and much less so for CAO. For example, the 72 h GSAO IC₅₀ is similar to the 24 h IC₅₀ for CAO.

CAO triggers the mitochondrial permeability transition.

30 GSAO has been shown to inactivate the mitochondrial inner membrane transporter adenine nucleotide translocase (ANT), which leads to proliferation arrest and cell death (Don et al., 2003). CAO also induces the mitochondrial permeability transition (Fig. 17).

References

Allen, J. D., Brinkhuis, R. F., Wijnholds, J., and Schinkel, A. H. (1999). The mouse *Bcrp1/Mxr/Abcp* gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. *Cancer Res* 59, 4237-4241.

5 Dilda, P. J., Decollogne, S., Rossiter-Thornton, M., and Hogg, P. J. (2005a). Para to ortho repositioning of the arsenical moiety of the angiogenesis inhibitor 4-(N-(S-glutathionylacetyl)amino)phenylarsenoxide results in a markedly increased cellular accumulation and antiproliferative activity. *Cancer Res* 65, 11729-11734.

10 Dilda, P. J., Don, A. S., Tanabe, K. M., Higgins, V. J., Allen, J. D., Dawes, I. W., and Hogg, P. J. (2005b). Mechanism of selectivity of an angiogenesis inhibitor from screening a genome-wide set of *Saccharomyces cerevisiae* deletion strains. *J Natl Cancer Inst* 97, 1539-1547.

15 Don, A. S., Kisker, O., Dilda, P., Donoghue, N., Zhao, X., Decollogne, S., Creighton, B., Flynn, E., Folkman, J., and Hogg, P. J. (2003). A peptide trivalent arsenical inhibits tumor angiogenesis by perturbing mitochondrial function in angiogenic endothelial cells. *Cancer Cell* 3, 497-509.

20 Evens, A. M., Tallman, M. S., and Gartenhaus, R. B. (2004). The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future. *Leuk Res* 28, 891-900.

25 Evers, R., Kool, M., Smith, A. J., van Deemter, L., de Haas, M., and Borst, P. (2000). Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport. *Br J Cancer* 83, 366-374.

20 Kobayashi, D., Nozawa, T., Imai, K., Nezu, J., Tsuji, A., and Tamai, I. (2003). Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. *J Pharmacol Exp Ther* 306, 703-708.

30 Kool, M., van der Linden, M., de Haas, M., Scheffer, G. L., de Vree, J. M., Smith, A. J., Jansen, G., Peters, G. J., Ponne, N., Scheper, R. J., *et al.* (1999). MRP3, an organic anion transporter able to transport anti-cancer drugs. *Proc Natl Acad Sci U S A* 96, 6914-6919.


Reiter, A., Lengfelder, E., and Grimwade, D. (2004). Pathogenesis, diagnosis and monitoring of residual disease in acute promyelocytic leukaemia. *Acta Haematol* 112, 55-67.

Vey, N. (2004). Arsenic trioxide for the treatment of myelodysplastic syndromes. *35 Expert Opin Pharmacother* 5, 613-621.

Wolff, N. C., Randle, D. E., Egorin, M. J., Minna, J. D., and Ilaria, R. L., Jr. (2004). Imatinib mesylate efficiently achieves therapeutic intratumor concentrations *in vivo* but has limited activity in a xenograft model of small cell lung cancer. *Clin Cancer Res* 10, 3528-3534.

CLAIMS:

1. A compound of general formula (I):



wherein

5 the As(OH)₂ group may be ortho-, meta- or para- to the N-atom on the phenyl ring;

R¹ is selected from hydrogen and C₁₋₃ alkyl;

10 R² and R³ may be the same or different and are independently selected from hydrogen, optionally substituted C₁₋₃ alkyl, optionally substituted cyclopropyl, optionally substituted C₂₋₃ alkenyl; and optionally substituted C₁₋₃ alkoxy;

R⁴ and R⁵ may be the same or different and are independently selected from hydrogen, optionally substituted C₁₋₃ alkyl, optionally substituted cyclopropyl, optionally substituted C₂₋₃ alkylene; and optionally substituted C₁₋₃ alkoxy;

m is an integer selected from 1, 2 and 3;

15 n is an integer selected from 1, 2 and 3;

* indicates a chiral carbon atom; and

salt and hydrates thereof, enantiomers and racemates thereof.


2. A compound according to claim 1, wherein R¹ is selected from hydrogen, methyl and ethyl.

20 3. A compound according to claim 1 or 2, wherein R² and R³ are independently selected from hydrogen, methyl, ethyl, methoxy, vinyl, hydroxymethyl, CF₃ and OCF₃.

25 4. A compound according to any one of claims 1 to 3, wherein R⁴ and R⁵ are independently selected from hydrogen, C₁₋₃ alkyl, C₂₋₃ alkenyl, C₁₋₃ alkoxy, halo-(C₁₋₃)alkoxy, hydroxy-(C₁₋₃)alkyl and halo(C₁₋₃)alkyl.


5. A compound according to claim 1, wherein the $\text{As}(\text{OH})_2$ group is ortho- or para- to the N-atom on the phenyl ring; R^1 is hydrogen or methyl; R^2 and R^3 are independently selected from hydrogen, methyl, ethyl, methoxy, vinyl, CH_2OH , CF_3 and OCF_3 ; R^4 and R^5 are independently selected from hydrogen, methyl, ethyl, CH_2OH , methoxy, vinyl, CF_3 and OCF_3 ; m is 1; and n is 1.

6. A compound according to claim 1 having the following structural formula:



and salts, hydrates, enantiomers and racemates thereof.

10 7. A compound according to claim 1 having the following structural formula:



and salts, hydrates, enantiomers and racemates thereof.

15 8. A compound according to claim 6 or 7, wherein the stereochemistry at the chiral carbon denoted * is (S), and salts and hydrates thereof.

9. A pharmaceutical composition comprising at least one compound of formula (I) according to any one of claims 1 to 8 or a salt or hydrate thereof, together with a pharmaceutically acceptable excipient, diluent or adjuvant.

10. A method of treating a cellular proliferative disease in a vertebrate, the method comprising administering to the vertebrate a therapeutically effective amount of a compound of formula (I) according to any one of claims 1 to 8, or a composition according to claim 9.

11. A method of inhibiting angiogenesis in a vertebrate, comprising administering to the vertebrate an effective amount of a compound of formula (I) according to any one of claims 1 to 8, or a composition according to claim 9.

12. A method of selectively inducing the mitochondrial permeability transition (MPT) in proliferating cells in a vertebrate comprising administering to the vertebrate a therapeutically effective amount a compound of formula (I) according to any one of claims 1 to 8, or a composition according to claim 9.

5 13. A method of inducing apoptosis in proliferating mammalian cells, comprising administering to the mammal an apoptosis-inducing amount of a compound of formula (I) according to any one of claims 1 to 8, or a composition according to claim 9.

10 14. A method of treating leukaemia or myelodysplastic syndrome in a vertebrate, comprising administering to the vertebrate a therapeutically effective amount of a compound of formula (I) according to any one of claims 1 to 8, or a composition according to claim 9.

15. The method according to claim 14, wherein the leukaemia is acute promyelocytic leukaemia (APL) or acute myelocytic leukaemia (AML).

16. Use of a compound according to any one of claims 1 to 8, for the manufacture of a medicament for treating cellular proliferation disease in a vertebrate.

17. Use of a compound according to any one of claims 1 to 8, for the manufacture of a medicament for inhibiting angiogenesis in a vertebrate.

18. Use of a compound according to any one of claims 1 to 8, for the manufacture of a medicament for selectively inducing the mitochondrial permeability transition (MPT) in a vertebrate.

19. Use of a compound according to any one of claims 1 to 8, for the manufacture of a medicament for inducing apoptosis in proliferating mammalian cells.

20. Use of a compound according to any one of claims 1 to 8, for the manufacture of a medicament for treating leukaemia or myelodysplastic syndrome in a vertebrate.

**Dated 3 July, 2012
NewSouth Innovations Pty Limited**

**Patent Attorneys for the Applicant/Nominated Person
SPRUSON & FERGUSON**





Figure 1

**Figure 2**




Figure 3

4/17




Figure 4






Figure 5

6/17

**Figure 6**

7/17

**Figure 7**




Figure 8

9/17





Figure 9

10/17

**Figure 10**






Figure 11

12/17

**Figure 12**

**Figure 13**




Figure 14




Figure 15





Figure 16

**Figure 17**